NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

NRDE2 缺陷会损害同源重组修复,并使肝细胞癌对 PARP 抑制剂更加敏感。

阅读:1
作者:Yahui Wang ,Xinyi Liu ,Xianbo Zuo ,Cuiling Wang ,Zheng Zhang ,Haitao Zhang ,Tao Zeng ,Shunqi Chen ,Mengyu Liu ,Hongxia Chen ,Qingfeng Song ,Qi Li ,Chenning Yang ,Yi Le ,Jinliang Xing ,Hongxin Zhang ,Jiaze An ,Weihua Jia ,Longli Kang ,Hongxing Zhang ,Hui Xie ,Jiazhou Ye ,Tianzhun Wu ,Fuchu He ,Xuejun Zhang ,Yuanfeng Li ,Gangqiao Zhou

Abstract

To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare-variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCC-associated genes, including NRDE2, RANBP17, RTEL1, and STEAP3. Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 × 10-9) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。